Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.35 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189437 | 1.00 | SUV39H2 (0.38) | SUV39H2ERAP2LNPEPERAP1CIT | |
| SCHEMBL10241746 | 0.95 | SUV39H2 (0.40) | SUV39H2ERAP2LNPEPERAP1CIT | |
| SCHEMBL10242338 | 0.95 | SUV39H2 (0.40) | SUV39H2ERAP2LNPEPERAP1CIT | |
| Hydrochloric Acid SCHEMBL623854 | 0.94 | SUV39H2 (0.39) | SUV39H2ERAP2LNPEPERAP1CIT | |
| SCHEMBL10189431 | 0.89 | CIT (0.35) | CITAAK1LMNARXFP1 | |
| SCHEMBL10189427 | 0.89 | S1PR1 (0.38) | CITAAK1LMNARXFP1 | |
| SCHEMBL10189429 | 0.89 | S1PR1 (0.38) | CITAAK1LMNARXFP1 | |
| SCHEMBL10189430 | 0.89 | CIT (0.35) | CITAAK1LMNARXFP1 | |
| SCHEMBL10189438 | 0.88 | LMNA (0.33) | CITAAK1LMNARXFP1 | |
| SCHEMBL10189440 | 0.88 | LMNA (0.33) | CITAAK1LMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | SUV39H2 2439/4885ERAP2 4040/4885LNPEP 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.